About evinacumab
ANGPTL3 monoclonal antibody
Used for
- Add-on treatment for homozygous familial hypercholesterolemia (HoFH), alongside other cholesterol-lowering treatments.
Usual adult dose
15 mg/kg by intravenous infusion every four weeks.
Usual dose in children
For HoFH from age 5 years: 15 mg/kg by intravenous infusion every four weeks.
Common side effects
- Common cold-like symptoms
- Flu-like illness
- Dizziness
- Nausea
Important warnings
- Infusion-related reactions can occur; serious allergic reactions are possible.
- Use with other cholesterol-lowering treatments; it does not replace them.
- Safety and effectiveness are not established for other cholesterol conditions.
Pregnancy
Human pregnancy information is limited. Potential fetal risk is uncertain; animal studies found no clear harm.
Breastfeeding
It is unknown whether evinacumab passes into breast milk or affects a nursing child.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.